Efficacy and safety of repeat courses of rituximab treatment in patients with severe refractory juvenile idiopathic arthritis

Clinical Rheumatology

Volumn 30, Issue 9, 2011, Pages 1163-1172

  Alexeeva, Ekaterina I ^a   Valieva, Saniya I ^a   Bzarova, Tatyana M ^a   Semikina, Elena L ^a   Isaeva, Kseniya B ^a   Lisitsyn, Alexander O ^a   Denisova, Rina V ^a   Chistyakova, Evgeniya G ^a  

^a INSTITUTE OF BIOMEDICAL CHEMISTRY   (Russian Federation)

Author keywords

B cells; Children; Juvenile idiopathic arthritis; Rituximab; Treatment

Indexed keywords

CYCLOSPORIN; GLUCOCORTICOID; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN M; INFLIXIMAB; METHOTREXATE; METHYLPREDNISOLONE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISOLONE; RITUXIMAB; TUMOR NECROSIS FACTOR INHIBITOR;

ABDOMINAL PAIN; ADENOID; ADOLESCENT; ARTICLE; BACKACHE; BLOOD PRESSURE; CARDITIS; CHILD; DISEASE SEVERITY; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG INFUSION; DRUG PULSE THERAPY; DRUG SAFETY; DYSPNEA; FEMALE; FLU LIKE SYNDROME; HEPATOMEGALY; HERPES SIMPLEX; HUMAN; IMMUNOGLOBULIN DEFICIENCY; IMMUNOTHERAPY; INFECTION; INJECTION SITE REACTION; JUVENILE RHEUMATOID ARTHRITIS; LOBAR PNEUMONIA; LYMPHADENOPATHY; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUTROPENIA; OTITIS; PRESCHOOL CHILD; PRIORITY JOURNAL; REMISSION; SCHOOL CHILD; SIDE EFFECT; SINUSITIS; SKIN INFECTION; SPLENOMEGALY; TREATMENT RESPONSE; VOMITING;

ADOLESCENT; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE RHEUMATOID; B-LYMPHOCYTES; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, MULTIPLE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; JOINTS; LYMPHOCYTE DEPLETION; MALE; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 80052616538     PISSN: 07703198     EISSN: 14349949     Source Type: Journal    
DOI: 10.1007/s10067-011-1720-7     Document Type: Article

References (30)

1. SE Gabriel 2001 The epidemiology of rheumatoid arthritis Rheum Dis Clin North Am 27 269 281 11396092 10.1016/S0889-857X(05)70201-5 1:STN:280: DC%2BD3MzivVKguw%3D%3D (Pubitemid 32488705)
2. HD El Gabalawy PE Lipsky 2002 Why do we not have a cure for rheumatoid arthritis? Arthritis Res 4 Suppl 3 S297 S301 12110149 10.1186/ar568
3. EL Nasonov 2005 Pharmacotherapy of rheumatoid arthritis: the 21st century Klin Med Mosk 83 8 12 16075638 1:CAS:528:DC%2BD2MXnvVOgtbk%3D
4. EL Nasonov 2006 Treatment of rheumatoid arthritis: current problem state Russ Med J 14 573 577
5. P Woo TR Southwood AM Prieur CJ Dore J Grainger J David C Ryder N Hasson A Hall I Lemelle 2000 Randomized, placebo-controlled, crossover trial of low-dose oral methotrexate in children with extended oligoarticular or systemic arthritis Arthritis Rheum 43 1849 1857 10943876 10.1002/1529-0131(200008)43: 8<1849::AID-ANR22>3.0.CO;2-F 1:CAS:528:DC%2BD3cXmtFKju7o%3D (Pubitemid 30640941)
6. Cassidy JT (2005) Textbook of paediatric rheumatology, 5th edn. Elsevier, Philadelphia
7. Alexeeva EI, Litvitsky PF (2007) Juvenile rheumatoid arthritis. Etiology. Pathogenesis. Clinics. Diagnostic and treatment algorithms. Guidelines for physicians, academicians, researchers. In: Baranov AA (ed) Academician of the Russian Academy of Medical Sciences, Moscow, pp 325-339
8. EL Nasonov 2008 Rituximab in the treatment of rheumatic diseases Nauchno-prakticheskaya revmatologia 1 3 10
9. JL Browning 2006 B cells move to centre stage: novel opportunities for autoimmune disease treatment Nat Rev Drug Discov 5 564 576 16816838 10.1038/nrd2085 1:CAS:528:DC%2BD28XmsVagsrY%3D (Pubitemid 43971191)
10. N Bizzaro R Tozzoli Y Shoenfeld 2007 Are we at a stage to predict autoimmune rheumatic diseases? Arthritis Rheum 56 1736 1744 17530702 10.1002/art.22708 1:CAS:528:DC%2BD2sXnsVOhtrk%3D (Pubitemid 47110373)
11. JC Edwards G Cambridge MJ Leandro 2006 B cell depletion therapy in rheumatic disease Best Pract Res Clin Rheumatol 20 915 928 16980214 10.1016/j.berh.2006.05.010 1:CAS:528:DC%2BD28Xps1Cnurk%3D (Pubitemid 44382384)
12. EL Nasonov 2006 New trends in the treatment of rheumatoid arthritis: perspectives of use of monoclonal anti-B-lymphocyte antibodies (rituximab) Russ Med J 25 1778 1782
13. ME Reff K Carner KS Chambers PC Chinn JE Leonard R Raab RA Newman N Hanna DR Anderson 1994 Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20 Blood 83 435 445 7506951 1:CAS:528: DyaK2cXhtVCnu70%3D (Pubitemid 24030569)
14. JC Edwards L Szczepañski J Szechiñski A Filipowicz-Sosnowska P Emery DR Close RM Stevens T Shaw 2004 Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis N Engl J Med 350 2572 2581 15201414 10.1056/NEJMoa032534 1:CAS:528:DC%2BD2cXkvFKntrc%3D (Pubitemid 38758544)
15. P Emery R Fleischmann A Filipowicz-Sosnowska J Schechtman L Szczepañski A Kavanaugh AJ Racewicz RF van Vollenhoven NF Li S Agarwal EW Hessey TM Shaw 2006 The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial Arthritis Rheum 54 1390 1400 16649186 10.1002/art.21778 1:CAS:528:DC%2BD28XlsFSquro%3D
16. SB Cohen P Emery MW Greenwald M Dougados RA Furie MC Genovese EC Keystone JE Loveless GR Burmester MW Cravets EW Hessey T Shaw MC Totoritis 2006 Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks Arthritis Rheum 54 2793 2806 16947627 10.1002/art.22025 1:CAS:528: DC%2BD28XhtFWksLjI (Pubitemid 44497758)
17. E Keystone P Emery CG Peterfy PP Tak S Cohen MC Genovese M Dougados GR Burmester M Greenwald TK Kvien S Williams D Hagerty MW Cravets T Shaw 2009 Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies Ann Rheum Dis 68 216 221 18388156 10.1136/ard.2007.085787 1:CAS:528: DC%2BD1MXisVSjs7o%3D
18. I Foeldvari B Bica F Dedeoglu 2009 Efficacy of rituximab in RF factor negative juvenile idiopathic arthritis Ann Rheum Dis 68 Suppl 3 502 abstract FRI0450
19. M El-Hallak BA Binstadt AM Leichtner CM Bennett EJ Neufeld RC Fuhlbrigge D Zurakowski RP Sundel 2007 Clinical effects and safety of rituximab for treatment of refractory pediatric autoimmune diseases J Pediatr 150 376 382 17382113 10.1016/j.jpeds.2006.10.067 1:CAS:528:DC%2BD2sXjsVequ7k%3D (Pubitemid 46437325)
20. JG Feito CA Pereda 2009 Rituximab therapy produced rapid and sustained clinical improvement in a patient with systemic onset juvenile idiopathic arthritis refractory to TNF alpha antagonists J Clin Rheumatol 15 363 365 20009975 10.1097/RHU.0b013e3181ba3c6f
21. M Kasher-Meron Y Uziel H Amital 2009 Successful treatment with B-cell depleting therapy for refractory systemic onset juvenile idiopathic arthritis: a case report Rheumatol Oxf 48 445 466 10.1093/rheumatology/ken492
22. A Kuek BL Hazleman JH Gaston AJ Ostör 2006 Successful treatment of refractory polyarticular juvenile idiopathic arthritis with rituximab Rheumatol (Oxf) 45 1448 1449 10.1093/rheumatology/kel301 1:STN:280:DC%2BD28nhslygtQ%3D%3D (Pubitemid 44605487)
23. J Narváez C Díaz-Torné X Juanola C Geli JM Llobet JM Nolla C Díaz-López 2009 Rituximab therapy for refractory systemic-onset juvenile idiopathic arthritis Ann Rheum Dis 68 607 608 19286909 10.1136/ard.2008.092106
24. EI Alexeeva EL Bzarova ASS Semikina 2006 Experience of the use of rituximab in a female patient with systemic juvenile rheumatoid arthritis Curr Ped (Russian) 5 96 100
25. EI Alexeeva EL Bzarova CI Valieva EL Semikina SS Akulova 2008 Rituximab: new opportunities in the treatment of severe refractory juvenile arthritis Curr Ped (Russian) 7 22 30
26. Denisova RV, Alexeeva EI, Albitskiy V, Yu et al (2009) Reliability, validity, and responsiveness of the Russian versions of the Pediatric Quality of Life Inventory™ Generic Core Scales and Rheumatology Module. Curr Ped (Russian) 8(1):30-41
27. Denisova RV, Alexeeva EI, Albitskiy V Yu et al (2008) Psychometric evaluation of Russian versions of the Pediatric Quality of Life Inventory™ Generic Core Scales and Rheumatology Module for children aged from 2 to 4 years old. Curr Ped (Russian) 7(5):39-45
28. CA Wallace N Ruperto E Giannini 2004 Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis J Rheumatol 31 2290 2294 15517647 (Pubitemid 39453253)
29. RF van Vollenhoven P Emery CO Bingham III EC Keystone R Fleischmann DE Furst K Macey M Sweetser A Kelman R Rao 2010 Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trials J Rheumatol 37 558 567 20110520 10.3899/jrheum.090856
30. S Dass EM Vital P Emery 2007 Development of psoriasis after B cell depletion with rituximab Arthritis Rheum 56 2715 2718 17665440 10.1002/art.22811 1:CAS:528:DC%2BD2sXhtVWqu7bE (Pubitemid 47237290)